Header Logo

Connection

JORGE CASTILLO to Waldenstrom Macroglobulinemia

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Waldenstrom Macroglobulinemia.
JORGE CASTILLO
Connection Strength
37.831
Waldenstrom Macroglobulinemia
  1. Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
    View in: PubMed
    Score: 0.797
  2. Zanubrutinib for the treatment of Bing-Neel syndrome. Br J Haematol. 2025 Apr; 206(4):1136-1140.
    View in: PubMed
    Score: 0.791
  3. Optimizing BTK Inhibition in Waldenstr?m Macroglobulinemia. J Natl Compr Canc Netw. 2024 05; 22(4).
    View in: PubMed
    Score: 0.748
  4. Waldenstr?m Macroglobulinemia: Targeted Agents Taking Center Stage. Drugs. 2024 Jan; 84(1):17-25.
    View in: PubMed
    Score: 0.727
  5. Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
    View in: PubMed
    Score: 0.705
  6. Waldenstr?m Macroglobulinemia: A Myriad of Effective Treatment Options, but Still Work to be Done. Hematol Oncol Clin North Am. 2023 08; 37(4):xiii-xiv.
    View in: PubMed
    Score: 0.700
  7. Novel Agents in Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2023 08; 37(4):751-760.
    View in: PubMed
    Score: 0.700
  8. Dose reductions in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2023 06; 201(5):897-904.
    View in: PubMed
    Score: 0.683
  9. Bruton tyrosine kinase inhibitors in the management of Waldenstr?m macroglobulinemia. Am J Hematol. 2023 02; 98(2):338-347.
    View in: PubMed
    Score: 0.682
  10. Natural history of Waldenstr?m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2022 05 01; 107(5):1163-1171.
    View in: PubMed
    Score: 0.651
  11. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Rev Anticancer Ther. 2022 05; 22(5):471-478.
    View in: PubMed
    Score: 0.650
  12. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr?m Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):547-556.
    View in: PubMed
    Score: 0.643
  13. A British view on the management of Waldenstr?m macroglobulinemia. Br J Haematol. 2022 04; 197(2):133-134.
    View in: PubMed
    Score: 0.641
  14. How to Sequence Therapies in Waldenstr?m Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92.
    View in: PubMed
    Score: 0.621
  15. Reducing treatment toxicity in Waldenstr?m macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676.
    View in: PubMed
    Score: 0.601
  16. Clinical application of genomics in Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815.
    View in: PubMed
    Score: 0.599
  17. Management of Waldenstr?m macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379.
    View in: PubMed
    Score: 0.591
  18. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
    View in: PubMed
    Score: 0.582
  19. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr?m macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959.
    View in: PubMed
    Score: 0.580
  20. Genomic Landscape of Waldenstr?m Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
    View in: PubMed
    Score: 0.559
  21. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2020 06; 61(6):1388-1394.
    View in: PubMed
    Score: 0.557
  22. CXCR4 mutational status does not impact outcomes in patients with Waldenstr?m macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98.
    View in: PubMed
    Score: 0.556
  23. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378.
    View in: PubMed
    Score: 0.555
  24. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562.
    View in: PubMed
    Score: 0.545
  25. How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285.
    View in: PubMed
    Score: 0.540
  26. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363.
    View in: PubMed
    Score: 0.535
  27. Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematol Oncol Clin North Am. 2019 08; 33(4):639-656.
    View in: PubMed
    Score: 0.529
  28. Ibrutinib and Rituximab in Waldenstr?m's Macroglobulinemia. N Engl J Med. 2018 11 15; 379(20):1973-4.
    View in: PubMed
    Score: 0.512
  29. Long survival in patients with Waldenstr?m macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802.
    View in: PubMed
    Score: 0.512
  30. Ibrutinib Monotherapy in Symptomatic, Treatment-Na?ve Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.502
  31. Genomic Landscape of Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752.
    View in: PubMed
    Score: 0.502
  32. Initial Evaluation of the Patient with Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):811-820.
    View in: PubMed
    Score: 0.501
  33. The real world of Waldenstr?m's macroglobulinaemia. Lancet Haematol. 2018 07; 5(7):e275-e276.
    View in: PubMed
    Score: 0.499
  34. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstr?m macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468.
    View in: PubMed
    Score: 0.495
  35. Fitting mSMART Into the Current Clinical Management of Waldenstr?m Macroglobulinemia. JAMA Oncol. 2018 05 01; 4(5):744-745.
    View in: PubMed
    Score: 0.493
  36. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014.
    View in: PubMed
    Score: 0.489
  37. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr?m macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85.
    View in: PubMed
    Score: 0.487
  38. Ibrutinib withdrawal symptoms in patients with Waldenstr?m macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310.
    View in: PubMed
    Score: 0.487
  39. Ibrutinib discontinuation in Waldenstr?m macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517.
    View in: PubMed
    Score: 0.485
  40. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71.
    View in: PubMed
    Score: 0.482
  41. Toward personalized treatment in Waldenstr?m macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
    View in: PubMed
    Score: 0.480
  42. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and?overall survival. Br J Haematol. 2018 02; 180(3):374-380.
    View in: PubMed
    Score: 0.479
  43. Comparative outcomes of immunochemotherapy regimens in Waldenstr?m macroglobulinaemia. Br J Haematol. 2017 10; 179(1):106-115.
    View in: PubMed
    Score: 0.466
  44. Novel approaches to targeting MYD88 in Waldenstr?m macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744.
    View in: PubMed
    Score: 0.466
  45. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
    View in: PubMed
    Score: 0.461
  46. MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr?m macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581.
    View in: PubMed
    Score: 0.444
  47. Idelalisib in Waldenstr?m macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004.
    View in: PubMed
    Score: 0.439
  48. Secondary malignancies in patients with multiple myeloma, Waldenstr?m macroglobulinemia and monoclonal gammopathy of undetermined significance. Leuk Lymphoma. 2017 04; 58(4):773-780.
    View in: PubMed
    Score: 0.439
  49. "All the soarings of my mind begin in my blood:" central nervous system complication of Waldenstr?m macroglobulinemia. Am J Hematol. 2016 Oct; 91(10):1057-60.
    View in: PubMed
    Score: 0.437
  50. Renal disease related to Waldenstr?m macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630.
    View in: PubMed
    Score: 0.437
  51. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr?m macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5.
    View in: PubMed
    Score: 0.437
  52. Atrial fibrillation associated with ibrutinib in Waldenstr?m macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3.
    View in: PubMed
    Score: 0.429
  53. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701.
    View in: PubMed
    Score: 0.426
  54. Central nervous system involvement by Waldenstr?m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
    View in: PubMed
    Score: 0.419
  55. Rituximab intolerance in patients with Waldenstr?m macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8.
    View in: PubMed
    Score: 0.415
  56. Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
    View in: PubMed
    Score: 0.392
  57. Overall survival and competing risks of death in patients with?Waldenstr?m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr; 169(1):81-9.
    View in: PubMed
    Score: 0.391
  58. Waldenstr?m macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70.
    View in: PubMed
    Score: 0.381
  59. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr?m's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
    View in: PubMed
    Score: 0.376
  60. Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 Jun; 100(6):980-986.
    View in: PubMed
    Score: 0.198
  61. Simplified Risk Stratification Model for Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42(21):2527-2536.
    View in: PubMed
    Score: 0.188
  62. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 04 09; 8(7):1639-1650.
    View in: PubMed
    Score: 0.186
  63. Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review. Leuk Lymphoma. 2024 Jul; 65(7):943-949.
    View in: PubMed
    Score: 0.185
  64. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr?m Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023 Nov 20; 41(33):5099-5106.
    View in: PubMed
    Score: 0.177
  65. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. JCO Glob Oncol. 2022 08; 8:e2100380.
    View in: PubMed
    Score: 0.166
  66. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstr?m macroglobulinemia. Blood Adv. 2022 04 12; 6(7):2230-2235.
    View in: PubMed
    Score: 0.162
  67. Venetoclax in Previously Treated Waldenstr?m Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
    View in: PubMed
    Score: 0.158
  68. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
    View in: PubMed
    Score: 0.156
  69. Plasmablastic lymphoma transformation in a patient with Waldenstr?m macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
    View in: PubMed
    Score: 0.155
  70. Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenstr?m macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253.
    View in: PubMed
    Score: 0.152
  71. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstr?m macroglobulinaemia. Br J Haematol. 2021 08; 194(4):730-733.
    View in: PubMed
    Score: 0.150
  72. Partial response or better at six?months is prognostic of superior progression-free survival in Waldenstr?m macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550.
    View in: PubMed
    Score: 0.147
  73. Consensus treatment recommendations from the tenth International Workshop for Waldenstr?m Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
    View in: PubMed
    Score: 0.147
  74. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr?m macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050.
    View in: PubMed
    Score: 0.147
  75. Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenstr?m's macroglobulinemia. Blood Adv. 2020 09 22; 4(18):4550-4553.
    View in: PubMed
    Score: 0.146
  76. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915.
    View in: PubMed
    Score: 0.142
  77. Genomic evolution of ibrutinib-resistant clones in Waldenstr?m macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170.
    View in: PubMed
    Score: 0.140
  78. Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702.
    View in: PubMed
    Score: 0.135
  79. CXCR4 mutations affect presentation and outcomes in patients with Waldenstr?m macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
    View in: PubMed
    Score: 0.134
  80. Progression Risk Stratification of Asymptomatic Waldenstr?m Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.132
  81. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305.
    View in: PubMed
    Score: 0.129
  82. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr?m macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790.
    View in: PubMed
    Score: 0.128
  83. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
    View in: PubMed
    Score: 0.128
  84. Profiling of circulating exosomal miRNAs in patients with Waldenstr?m Macroglobulinemia. PLoS One. 2018; 13(10):e0204589.
    View in: PubMed
    Score: 0.127
  85. Waldenstr?m Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematol Oncol Clin North Am. 2018 10; 32(5):xiii-xiv.
    View in: PubMed
    Score: 0.127
  86. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
    View in: PubMed
    Score: 0.126
  87. True, true unrelated? Coexistence of Waldenstr?m macroglobulinemia and cardiac transthyretin amyloidosis. Haematologica. 2018 08; 103(8):e374-e376.
    View in: PubMed
    Score: 0.123
  88. Genomics, Signaling, and Treatment of Waldenstr?m Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001.
    View in: PubMed
    Score: 0.113
  89. Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
    View in: PubMed
    Score: 0.112
  90. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
    View in: PubMed
    Score: 0.111
  91. Future therapeutic options for patients with Waldenstr?m macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215.
    View in: PubMed
    Score: 0.110
  92. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341.
    View in: PubMed
    Score: 0.109
  93. Recommendations for the diagnosis and initial evaluation of patients with Waldenstr?m Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstr?m Macroglobulinaemia. Br J Haematol. 2016 10; 175(1):77-86.
    View in: PubMed
    Score: 0.109
  94. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr?m macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
    View in: PubMed
    Score: 0.108
  95. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813.
    View in: PubMed
    Score: 0.107
  96. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824.
    View in: PubMed
    Score: 0.106
  97. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenstr?m macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606.
    View in: PubMed
    Score: 0.106
  98. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr?m Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
    View in: PubMed
    Score: 0.105
  99. Survival outcomes of secondary cancers in patients with Waldenstr?m macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701.
    View in: PubMed
    Score: 0.101
  100. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
    View in: PubMed
    Score: 0.100
  101. Ibrutinib in previously treated Waldenstr?m's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
    View in: PubMed
    Score: 0.100
  102. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8.
    View in: PubMed
    Score: 0.098
  103. Extramedullary Waldenstr?m macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
    View in: PubMed
    Score: 0.097
  104. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr?m macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7.
    View in: PubMed
    Score: 0.097
  105. Survival trends in Waldenstr?m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19; 123(25):3999-4000.
    View in: PubMed
    Score: 0.094
  106. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.